New shot aims to silence hepatitis b virus for good
NCT ID NCT07630727
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been treated and those already on antiviral therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AHB-171 injection
What this could lead to
If successful, this could point toward a functional cure for chronic hepatitis B, where the virus is suppressed to very low or undetectable levels without lifelong medication.
What could go wrong
This is an early Phase 2 trial with only 138 participants, so results may not apply to everyone. The treatment may not achieve lasting viral suppression, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AusperBio Investigational Site
Jilin City, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••